Background:Colorectal cancer (CRC) is a common malignant tumor of the gastrointestinal tract, constituting 10% of new colorectal cancer cases each year. Despite major breakthroughs in the treatment of colorectal cancer, 40–50% of patients are likely to develop local or distant tumor recurrences, and survival rates are poor.
Aim of the workis to evaluate the levels  of annexin A3 and thymidine phosphorylase in patients with colorectal cancer and compare these levels with control persons and  to ascertain whether annexin A3 and thymidine phosphorylase  are involved in the progression of the colorectal cancer and their impact on patient outcome.
Patients and methods: This study was performed at Sohag University Hospital from December 2015 to December 2016 , Seventy five patients were enrolled in the study and divided into two groups. 60 patients with colorectal cancer, 15 patients with benign colorectal disease. All were matched for age and sex, for each participant body mass index (BMI), blood pressure, Annexin A3 by Eliza kit , Thymidine phosphorylase by colorimetric method were performed.
Results:There were significant relations between Annexin A3and Thymidine phosphorylase and age.Significant relations were observed between Annexin A3and Thymidine phosphorylase and type of cancer.Strong positive correlation  was observed between Annexin A3and Thymidine phosphorylase.
Conculsion :we conclude that  both of  Annexin A3 and Thymidine phosphorylase were positive correlated with type and grade of colorectal cancer .So using Annexin A3 and thymidine phosphorylase as positive biomarker in the  progression of  colorectal cancer may be beneficial.